Skip to main content
ALVOW logo

Alvotech (ALVOW) Stock Price & Analysis

Alvotech (ALVOW) — price $0.2753 (0.00%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.2753 $0.00 (0.00%)

Alvotech · ALVOW

Alvotech Holdings SA develops and manufactures biosimilars for global markets. The company is based in Iceland and aims to provide more affordable alternatives to branded biologic drugs.

Price as of Nov 19, 2026

Key Statistics

Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • BHC · Bausch Health Companies Inc. · 30 /100
  • TAK · Takeda Pharmaceutical Company Limited · 73 /100
  • TEVA · Teva Pharmaceutical Industries Limited · 57 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.2753
Change on the day0.00%
52-week range$0.1188 – $1.52
Shares traded on the day2.2K

Price & events

Other perspectives

Council score for Alvotech (ALVOW): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Overvalued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Jul 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jul 29, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Alvotech (ALVOW), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Alvotech (ALVOW) is the company analyzed here. It employs 1,460 people and is led by Lisa Graver. In Q3 FY2026 it reported revenue of $111M and net income of -$75M.

2 · Latest results

What do the latest results show for Alvotech (ALVOW)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $111M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$111M-$75M-$0.23 (diluted)
Q2 FY2026$106M-$67M-$0.19 (diluted)
Q1 FY2026$106M$1M$0.0031 (diluted)
Q4 FY2025$166M-$109M-$0.43 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Alvotech (ALVOW)?

Short answer · as of

The distress and quality screens read Altman Z -1.03 · Piotroski F 1. Trailing ratios: ROE 97.2% · ROA -15.4% · current ratio 1.78 · earnings yield -18.1% · free-cash-flow yield -23.8%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.03 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ALVOW in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ALVOW in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Alvotech Stock: Key Questions Answered

These answers are editorial: 1 of these 1 answer is drawn from the ALVOW research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What does Alvotech do?

Alvotech Holdings SA develops and manufactures biosimilars, which are near-identical copies of original biologic drugs. These biosimilars offer a more affordable alternative to expensive branded biologics, addressing the growing demand for cost-effective healthcare solutions.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.